Anagrelide 5240 1 Mg 00172 5240 60 Medication Summary
No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication?
This medication is described in FDA/DailyMed prescribing information. No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication used for?
Anagrelide capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
What should I know before taking it?
None.
What important warnings are listed?
Cardiovascular Toxicity: QT prolongation and ventricular tachycardia have been reported with anagrelide. Obtain a pre-treatment cardiovascular examination including an ECG in all patients. Monitor patients for cardiovascular effects. (5.1)Pulmonary Hypertension: Assess underlying cardiopulmonary disease prior to initiating therapy. (5.2)Bleeding Risk: Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding. (5.3)
How is this medication usually taken?
Anagrelide Capsules USP 0.5 mg are available as size #4 hard gelatin capsules with light grey opaque colored cap and coral opaque colored body, imprinted with black ink as "ESJAY 480" on cap, and "ESJAY 480" on body, filled with white to off-white powder containing 0.5 mg of anagrelide base (as anagrelide hydrochloride). Anagrelide Capsules USP 1 mg are available as are size #4 hard gelatin capsules with light grey opaque colored cap and aqua blue opaque colored body, imprinted with black ink as "ESJAY 481" on cap, and "ESJAY 481" on body, filled with white to off-white powder containing 1 mg of anagrelide base (as anagrelide hydrochloride).
What side effects are listed?
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Cardiovascular Toxicity [see Warnings and Precautions (5.1)] Pulmonary Hypertension [see Warnings and Precautions (5.2)] Bleeding Risk [see Warnings and Precautions (5.3)] Pulmonary Toxicity [see Warnings and Precautions (5.4)]
What interactions are listed?
Other PDE 3 inhibitors: Exacerbation of inotropic effects (7.2) Aspirin and Drugs that Increase Bleeding Risk: Increased risk of bleeding with concomitant use (7.3)
Where can I find the official prescribing information?
Review the full prescribing information on DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56b3959d-4b6b-413f-b753-9d4c20c07466
⚠️ Disclaimer
This summary is for educational purposes only and is not medical advice. Always consult your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine. Read full medical disclaimer.